Energy Conference: Decarbonization - A Business Perspective REGISTER

The New Jersey Innovation Institute, an NJIT Corporation, and Rutgers University have announced plans to form the New Jersey Continuous Manufacturing Institute (NJCMI) to advance innovative manufacturing technologies in the pharmaceutical industry.

The NJCMI serves as a center of excellence combining state-of-the-art technologies, infrastructure, facilities and technical expertise to support the development and continuous manufacturing of products for the pharmaceutical industry. In addition, it provides training, education and workforce development solutions for those who want to expand or gain additional training and expertise in pharmaceutical manufacturing.

In making the announcement Monday, Dr. Donald H. Sebastian, president of NJII said: “This partnership with Rutgers builds on over a decade of leading edge R&D, and deep faculty expertise that NJCMI can leverage to make available pilot-scale technologies that meet pharmaceutical industry demands for higher production volume, greater efficiency and reduced cost.  I expect the center will be a strong magnet attracting all the links of the pharmaceutical value chain to make New Jersey a place of business.”

The NJCMI facility features Process Development Pilot Plants for solid dosage forms and biologics, as well as cGMP suites for production. In addition, it provides individual Unit Operations labs for process optimization and control, modeling and automation. It also offers designated classrooms and training labs for collaborative learning experiences and workforce development.

“NJCMI brings together a complete range of expertise and knowledge to develop innovative biopharmaceutical processing technologies,” said Dr. Christopher J. Molloy, senior vice president, Rutgers Office of Research & Economic Development.

“Our team is led by a core of professionals with more than 100 years of combined experience in biopharmaceutical manufacturing process development, biochemical and chemical engineering,” Dr. Molloy said. “Together, Rutgers and NJII, through the NJCMI, are meeting the challenges for cost effective approaches to the continuous production of both new and existing classes of pharmaceuticals.”

The New Jersey Innovation Institute (NJII) is an NJIT corporation that applies the intellectual and technological resources of the state’s science and technology university to challenges identified by industry partners. Through its Innovation Labs (iLabs), NJII brings NJIT expertise to key economic sectors, including healthcare delivery systems, bio-pharmaceutical production, civil infrastructure, defense and homeland security, and financial services.